RxDoctor Payments Data

Kristofer Dosh, MD

Cardiovascular Disease · Green Bay, WINPI 1790999092

Payments from drug & device makers

$15,792in general payments, 2019–2025

Across 148 payments — averaging $106.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$7K
  • Boston Scientific$4K
  • Edwards Lifesciences$2K
  • Abbott$2K
  • Medtronic$538
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$227
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$4,16547%
  • Food & beverage$4,59652%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,792 in reported general payments places this provider in the 80th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$114,185
Medicare patients
849
Services billed
1,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$109,727
XareltoRivaroxaban22$24,710
EntrestoSacubitril/Valsartan26$19,229
Repatha SureclickEvolocumab22$17,815
Amiodarone Hcl24$1,339
Metoprolol Succinate89$1,287
Atorvastatin Calcium63$1,097
ClopidogrelClopidogrel Bisulfate69$984
Rosuvastatin Calcium59$777
Isosorbide Mononitrate ErIsosorbide Mononitrate79$774
Amlodipine Besylate77$604
Losartan Potassium50$557
Carvedilol51$552
Ezetimibe27$542
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$109,727107 claims
Johnson & JohnsonXarelto$57$24,71022 claims
NovartisEntresto$207$19,22926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →